MarY WHEELER

Mary founded BioRock Ventures in 2019. BioRock is a venture fund, investing in early stage therapeutics startups, with a particular emphasis on seed-sized first checks through Series A.

Select past first-check investments include Vaxcyte (NASDAQ: PCVX), 4DMT (NASDAQ: FDMT) and AN2 Therapeutics (NASDAQ: ANTX).

Mary began venture investing a decade ago at Johnson & Johnson, where she helped form and put first money into biopharma startups. She subsequently served as consulting CBO for several dozen early-stage ventures around the world while also leading a syndicate of angel investors.

Prior to investing she has two decades of operating experience as a therapeutics startup founder in Boston followed by roles leading negotiations, business and technical evaluations for M&A and licensing deals, as well as strategy roles at large and medium pharmaceuticals companies, Johnson & Johnson and Forest (now part of Abbvie).

Mary is a Kauffman Fellow, earned an MBA from MIT Sloan, a PhD from Princeton University and an undergraduate degree from Yale University. She lives in the Bay Area with her family.